Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis
Metrics: PDF 845 views | HTML 2847 views | ?
Xueyong Liu1, Zhan Zhang2, Chunbo Deng3, Yihao Tian1 and Xun Ma1
1Department of Spine and Joint Surgery, Shengjing Hospital of China Medical University, Shenyang, China
2Department of Spine Surgery, Shengjing Hospital of China Medical University, Shenyang, China
3Department of Orthopedics, Fengtian Hospital of Shenyang Medical College, Shenyang, China
Xueyong Liu, email: firstname.lastname@example.org
Keywords: ERCC, meta-analysis, polymorphism, osteosarcoma, prognosis
Received: October 10, 2016 Accepted: July 11, 2017 Published: July 19, 2017
To investigate correlations between excision repair cross-complementation group 1 (ERCC1) and 2 (ERCC2) polymorphisms and osteosarcoma prognosis, we conducted a meta-analysis of studies published through October 2016. Studies were identified in the PubMed, ScienceDirect, Springer, and Web of Science databases using preferred reporting items for systematic reviews and meta-analyses (PRISMA). Odds ratios (ORs) or hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS), tumor response (TR), and event-free survival (EFS) were estimated. Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated. Each of these studies scored > 6 on the Newcastle-Ottawa Scale (NOS). We found that only one SNP, ERCC1 rs11615, correlated with improved OS and TR. The HR of T vs. C for OS was 1.455 (T/C, 95% CI = 1.151–1.839, P = 0.002, I2 = 37.80%). The OR of T vs. C for good TR was 0.554 (T/C, 95% CI = 0.437–0.702, P < 0.001, I2 = 0%). Few significant outcome was observed in subgroup analyses stratified based on study characteristics with adjustments for potential confounders. Our results suggest that ERCC1 rs11615 CC is associated with a better clinical outcome. This suggests rs11615 may be a useful genetic marker for predicting osteosarcoma prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.